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Abstract We did the experiments to search for amino acids that
affect quinidine binding to the HERG channel, and have
identified an amino acid whose change by mutation affects the
binding of various drugs. The residue is located at position 647 in
the S6 and is not involved in the recently identified methane-
sulfonanilide binding pocket. The homology model of the HERG
channel indicated that the residue faces toward the outside of the
channel pore. We conclude that the residue at position 647 does
not interact directly with drug molecules but plays an important
role in keeping the binding site’s high affinity for drugs. ß 2001
Published by Elsevier Science B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
The rapidly activating delayed recti¢er K current (IKr)
plays an important role in determining cardiac action poten-
tial duration (APD). Reduction of IKr results in prolongation
of APD and long QT syndrome (LQTS) that can lead to life-
threatening ventricular tachyarrhythmia [1^3]. Prolongation
of the QT interval may be congenital or secondary (acquired).
Congenital LQTS-2 has been linked to lesions in the human
ether-a-go-go-related gene (HERG) that encodes a pore-form-
ing subunit of the IKr channel [4^6]. Acquired LQTS has been
reported to result from a number of medications that inhibit
IKr (e.g. several antiarrhythmic drugs, antipsychotic drugs and
antihistaminergic drugs) [7^10]. The class I antiarrhythmic
drug quinidine has a broad spectrum of channel-blocking ac-
tivity and is known to cause QT prolongation which can be
both antiarrhythmic and proarrhythmic [11,12]. Quinidine
blocks not only the cardiac Na channel but also many car-
diac K channels including IKr. The proarrhythmic activity of
quinidine is most likely to be caused by excessive block of IKr.
Molecular analyses for the quinidine binding site have been
carried out for the cloned human cardiac K channel hKv1.5
and rat cardiac K channel rKv1.4 [13^16]. For both channels
the equivalent residue in the sixth transmembrane segment
(S6) has been identi¢ed as a molecular determinant of quini-
dine binding [15,16]. The important role of the S6 in drug
binding has been demonstrated not only for the above two
K channels, but also Na, Ca2 and other K channels [17^
22]. Recently, Phe at position 656, which is located on the
C-terminal half of the S6, was reported to be a molecular
determinant of high a⁄nity dofetilide binding to the HERG
channel [23]. Subsequently, an alanine-scanning mutagenesis
study identi¢ed the MK499 binding site that is composed of
¢ve^seven amino acids located on the S6 and the pore helix
[24]. In addition to identi¢cation of drug binding sites, a
number of studies demonstrated that loss of rapid C-type
inactivation of the HERG channel resulted in reduced a⁄nity
for various drugs [25^27]. The present study was designed to
search for amino acid residue(s) that a¡ect quinidine binding
to the HERG channel. We have focused on aromatic residues
in the S6 domain and have identi¢ed an amino acid residue,
Ile647, whose substitution with Phe reduces the e¡ect of qui-
nidine probably by an allosteric manner. Although the residue
is not in the recently identi¢ed methanesulfonanilide binding
pocket [24], the I647F mutation a¡ected the binding of not
only quinidine but also E-4031 (a methanesulfonanilide) and
terfenadine (an antihistaminergic drug).
2. Materials and methods
The plasmid containing HERG cDNA (HERG/pGH19) was gen-
erously provided by Dr. G.A. Robertson (University of Wisconsin,
Madison, WI, USA) [6]. The origin of the pGH19 vector is the pGHE
expression vector constructed by Liman et al. [28].
2.1. In vitro mutagenesis
Point mutations in the S6 of HERG were generated by one-step
PCR mutagenesis utilizing two unique restriction sites (BglII at nu-
cleotide 1913 and SphI at nucleotide 2310). The BglII site is at the
beginning of the S6 and the SphI site is in the C-terminal region.
Sense primers containing the desired mutations started two bases up-
stream of the BglII site and extended four^seven bases from the mu-
tations. An antisense primer used for construction of the mutants
corresponded to nucleotides 2312^2332. In a 100 Wl PCR reaction,
50 pmol of each primer, 0.2 Wg of HERG cDNA, and 0.125 units
of Pyrobest DNA polymerase (Takara, Osaka, Japan) were used.
Reaction temperatures were varied using a thermal cycler (Perkin-
Elmer, model 2400): 98‡C, 25 s; 60‡C, 30 s; and 72‡C, 90 s for 20
cycles. The ampli¢ed fragment was digested with BglII and SphI and
ligated to HERG between the two restriction enzyme sites. In addition
to the point mutants, two amino-terminal deletion mutants (HERG
WTv2-345 and I647Fv2-345) were constructed by PCR. The sense
primer corresponded to nucleotides 1063^1089, and contained an
ATG and BamHI site (unique in the multiple cloning site of the
vector) at the 5P end. The antisense primer corresponded to nucleo-
tides 2115^2134. PCR conditions were the same as above. The ampli-
¢ed fragment digested with BamHI and BglII was ligated to WT or
I647F between the two restriction enzyme sites. Sequences of all the
fragments generated by PCR in the mutants were veri¢ed by the
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dideoxy chain termination method using a DNA sequencer (Applied
Biosystems, model 310, Tokyo, Japan).
2.2. Expression and current recording
The pGH19 vectors containing the constructs were linearized with
NotI, and capped cRNAs were prepared from these templates with T7
RNA polymerase (Stratagene, La Jolla, CA, USA). Transcribed
RNAs were dissolved in sterile water at a ¢nal concentration of
0.2^0.4 Wg/Wl. Oocyte preparation and electrophysiological measure-
ments were carried out essentially as reported previously [29]. Defol-
liculated Xenopus oocytes (stage V^VI) were injected with 45.6 nl of
cRNA using a motor-driven injector (Drummond, PA, USA). The
injected oocytes were incubated in Barth’s medium supplemented
with penicillin G (71.5 units/ml) and streptomycin (35.9 Wg/ml) at
18‡C for 2^6 days before electrophysiological measurements. The
K currents were recorded by a conventional two-microelectrode volt-
age clamp method with 3 M KCl-¢lled electrodes. The bath recording
solution consisted of ND 96 (96 mM NaCl, 2 mM KCl, 1.8 mM
CaCl2, 1 mM MgCl2, 5 mM HEPES, pH 7.4). All electrophysiological
measurements were carried out at room temperature (21 þ 1‡C).
Data are expressed as mean þ S.E.M. The statistical signi¢cance was
evaluated using Student’s unpaired t-test. A P value smaller than 0.05
was considered to be signi¢cant.
3. Results and discussion
3.1. In£uence of the S6 mutations on the e¡ects of quinidine
Fig. 1 shows a sequence alignment of homologous regions
from the pore-lining helix of selected K channels. It has been
demonstrated that the residue at position 505 of hKv1.5 and
the equivalent residue of rKv1.4 (at position 529 of rKv1.4v3-
25) play an important role in determining the binding a⁄nity
for quinidine. In hKv1.5, it has been suggested that hydro-
phobicity of the side chain at the residue 505 is a major de-
terminant of the binding a⁄nity for quinidine: the increased
the hydrophobicity the increased the a⁄nity [15]. In
rKv1.4v3-25, it has been suggested that steric hindrance im-
posed by the side chain at position 529 is an important factor
in determining the a⁄nity: Phe (a bulky hydrophobic residue)
at position 529 markedly decreased the a⁄nity for quinidine
[16]. Therefore, we ¢rst investigated whether the equivalent
residue of HERG (M651) is responsible for quinidine binding.
Since IKs is much less sensitive than IKr to many drugs includ-
ing quinidine, we have substituted the M651 with the corre-
sponding residue of KvLQT1 that encodes a pore-forming
subunit of IKs [30^32]. Fig. 2A and C show representative
current traces before and after application of quinidine and
I^V relationships for HERG WT and the M651F, respec-
tively. When e¡ects of 10 WM quinidine were compared,
WT currents were inhibited by 59.7 þ 2.7%, whereas M651F
currents were inhibited by 44.0 þ 3.2% (Fig. 2E). The di¡er-
ence between these values was signi¢cant but small, which
suggests that the equivalent residue (M651) does not play a
crucial role in quinidine binding to the HERG channel. Re-
cently, Sanguinetti’s group have identi¢ed the methanesulfo-
nanilide binding pocket of the HERG channel using alanine-
scanning mutagenesis and have demonstrated the importance
of benzene rings in drug binding (not only for methanesulfo-
nanilides but also for other drugs) [24]. In addition, quinidine
binding to rKv1.4 is reduced by Phe substitution [16]. There-
fore, we have focused on aromatic residues in the S6 of both
HERG and KvLQT1, and substituted the residues of the
HERG with the corresponding residues of the KvLQT1. We
have found that substitution of Ile647 of the HERG with Phe
reduced the e¡ects of quinidine. Representative current traces
and I^V relationships of the I647F are shown in Fig. 2B.
Fig. 1. Alignment of K channel pore-lining helices. Mutated amino
acids of HERG and the corresponding residues of KvLQT1 are
shaded. T505 of hKv1.5 and T552 of rKv1.4 (T529 of rKv1.4v3-25)
play an important role in quinidine binding. F656 of HERG was re-
ported to be a molecular determinant of dofetilide binding. Residues
predicted to line the channel pore, based on the KcsA structure, are
boxed.
Fig. 2. I647F mutation reduces e¡ects of quinidine. Current traces
before and after application of 10 WM quinidine are shown in the
left and middle panel: HERG WT (A), I647F (B), M651F (C), and
Y652F (D). Respective control I^V relationships for currents at the
end of depolarizing pulse (open circle) and peak tail currents (closed
circle) are shown in the right panel. Currents were elicited by 2 s
depolarizing pulses ranging from 370 mV to +40 mV in 10 mV in-
crements. The holding potential was 380 mV and return potential
was to 360 mV. E: E¡ects of 10 WM quinidine were evaluated by
tail currents at 360 mV following the depolarizing pulse to 0 mV
after 20 min exposure to the drug. Currents are expressed as relative
values to control currents before quinidine application. WT (n = 10),
I647F (n = 5), M651F (n = 7), and Y652F (n = 9). *P6 0.05,
**P6 0.01.
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Quinidine (10 WM) inhibited the I647F currents only by
9.6 þ 3.1% (Fig. 2B, E). Another mutation which substituted
Tyr652 with Phe (Y652F) markedly a¡ected the gating ki-
netics but had little in£uence on block by quinidine (Fig.
2D, E). This result indicates that loss of the hydroxyl side
group has no in£uence on quinidine binding, and is in line
with the important role of the aromatic residue at position
652 in drug binding, which has been reported in the alanine-
scanning study [24].
3.2. In£uence of other substitutions of I647
We constructed other point mutants of I647 to investigate
whether Ile at position 647 is essential for high a⁄nity quini-
dine binding. Fig. 3C shows concentration^inhibition curves
for HERG WT, the I647F and I647A. The I647F mutation
increased the IC50 for quinidine 6-fold: 8.6 þ 0.68 WM for WT
and 49.1 þ 8.64 WM for the I647F. In contrast, the I647A had
little in£uence on the e¡ects of quinidine. This result indicates
that the I647 is not essential for high a⁄nity quinidine bind-
ing. Another mutation, I647Y, that is less hydrophobic than
I647F but introduces an aromatic ring at 647 reduced e¡ects
of quinidine. Inhibition of I647Y currents by 10 WM quinidine
Fig. 3. I647Y mutation reduces e¡ects of quinidine but I647A muta-
tion has no in£uence. A (I647A), B (I647Y): Current traces before
and after application of 10 WM quinidine are shown in the left and
right panel, respectively. Pulse protocols are the same as in Fig. 2.
C: Concentration^inhibition curves for HERG WT (open circle;
n = 8), I647F (closed circle; n = 5) and I647A (open square; n = 7).
Quinidine was applied in a cumulative manner. D: E¡ects of 10 WM
quinidine on I647Y were compared with those on WT and I647F.
Data on WT and I647F are the same as in Fig. 2E.
6
Fig. 4. Restoration of deactivation in I647F does not restore e¡ects of quinidine. A: Current traces of WT, WTv2-354, I647F, and I647Fv2-
354 are shown. Pulse protocols are the same as in Fig. 2. The N-terminal deletion accelerated the deactivation both for WT and I647F. When
the decaying phase of the tail current at 380 mV was ¢t with double exponential function, the rapid component of time constant was
171.2 þ 17.25 ms for WT (n = 8), 20.5 þ 1.54 ms for WTv2-354 (n = 5), and 56.9 þ 45.3 ms for I647Fv2-354 (n = 4). The tail current of the I647F
could not be ¢t well with double exponential function and was ¢t with single exponential function; the time constant was 928.9 þ 45.5 ms
(n = 5). B: E¡ects of 10 WM quinidine on WTv2-354 and I647Fv2-354 were compared with those on WT and I647F. Data on WT and I647F
are the same as in Fig. 2E. C: E¡ects of E-4031 (10 WM) and terfenadine (1 WM) on HERG WT and I647F currents were similarly evaluated.
**P6 0.01.
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was 32.0 þ 5.40%, which is signi¢cantly smaller than that of
WT (59.7 þ 2.67%) (Fig. 3D). Since inhibition of I647Y by
quinidine was larger than that of the I647F currents, the hy-
droxyl side group might have favorable in£uence on quinidine
binding. However, these results suggest that an aromatic ring
at 647 reduces quinidine binding.
3.3. E¡ects of quinidine on amino-terminal deletion mutants
As shown in Figs. 2B and 3A and B, the I647F and I647Y
mutations resulted in slowing of deactivation, whereas the
I647A mutation had no marked e¡ects on the deactivation.
Therefore, we investigated whether the change in deactivation
kinetics itself is responsible for the decreased a⁄nity of the
mutants for quinidine. Since it has been reported that the
amino-terminus regulates deactivation of HERG current and
the deletion of the domain results in acceleration of deactiva-
tion [33], we constructed the amino-terminal deletion mutant
of I647F (I647Fv2-354). As expected, deactivation of the cur-
rents of I647Fv2-354 was accelerated (Fig. 4A). Fig. 4B shows
the e¡ects of 10 WM quinidine on the currents of WT, WTv2-
354, I647F and I647Fv2-354. The e¡ects of quinidine tended
to be smaller in the deletion mutant than in its parent chan-
nel; the inhibition was 59.7 þ 2.67% (WT), 65.5 þ 3.84%
(WTv2-354; NS vs. WT), 9.7 þ 3.42% (I647F) and
28.8 þ 4.95% (I647Fv2-354; P6 0.05 vs. I647F). However,
when HERG WT and I647Fv2-354 were compared, the e¡ect
of quinidine was much smaller in I647Fv2-354, while the cur-
rents of I647Fv2-354 deactivated faster than WT. Thus,
although the slower deactivation kinetics might be partly in-
volved in the reduced a⁄nity for quinidine, the I647F muta-
tion a¡ects quinidine binding besides changing the deactiva-
tion kinetics.
3.4. E¡ects of E-4031 and terfenadine on the I647F
The alanine-scanning study has demonstrated that Y652
and F656 of the HERG channel are crucial for high a⁄nity
binding of both methanesulfonanilides and other unrelated
compounds. When mutated to Ala, only the two residues
markedly reduced the a⁄nity simultaneously for a methane-
sulfonanilide (MK499) and other drugs (terfenadine and cis-
apride). In contrast, mutation of two other residues (Val625
and Gly648) to Ala dramatically reduced the a⁄nity for
MK499 without a¡ecting the a⁄nity for terfenadine and cis-
apride. The mutations of V625 and G648 were thought to
disrupt the MK499 binding site by altering the size or shape
of the methanesulfonanilide binding pocket. Since the I647F
mutation reduced the e¡ects of quinidine, we examined the
e¡ects of E-4031 and terfenadine on the I647F currents.
E-4031 (10 WM) inhibited WT currents by 89.1 þ 0.74%,
whereas it inhibited the I647F currents by 31.3 þ 1.84% (Fig.
4C). In our experimental conditions, 1 WM terfenadine inhib-
ited WT currents by 38.0 þ 1.84% and I647F currents only by
6.9 þ 1.20% (Fig. 4C). Thus, the I647F mutation a¡ected bind-
ing of a variety of drugs including methanesulfonanilides.
3.5. A homology model
Sanguinetti’s group created a homology model of the
HERG channel by using the KcsA structure as the template.
Their model has demonstrated that three residues in the S6
(G648, Y652, and F656) whose mutation to Ala substantially
reduced the sensitivity to MK499 face toward the inside of the
channel pore. With the model and electrophysiological data,
they have suggested that the two aromatic residues directly
interact with drug molecules and G648 forms the one end of
the methanesulfonanilide binding pocket. We generated a sim-
ilar homology model of the HERG I647F channel by using
Fig. 5. A homology model of the HERG I647F mutant channel.
Side view (A) and top view (B) of the I647F channel. F647, Y652
and F656 are shown as a ball and stick model: F647 is yellow,
Y652 is blue, and F656 is red. F647 faces toward outside of the
channel pore. The KcsA structure retrieved from the Protein Data
Bank was used as the template structure for a homology model.
The homology model was created by MOE (2000.02; Chemical
Computing Group Inc., Montreal, QC, Canada).
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MOE (2000.02; Chemical Computing Group Inc., Montreal,
QC, Canada) to visualize location of F647 (Fig. 5). The model
shows that F647 faces toward the outside of the channel pore
to the outer helix of the S5. Therefore the F647 could not
directly interact with drug molecules. It has been reported that
F656, one of the important aromatic residues in the methane-
sulfonanilide binding site, reduced the a⁄nity not only for
dofetilide but also for quinidine when mutated to Val [23].
In£uence of the F656V mutation on the e¡ects of quinidine
is greater than that of the I647F mutation we studied, which is
consistent with the indirect in£uence of the I647F mutation on
the binding. Our results indicate that an amino acid residue at
position 647 plays an important role in terms of keeping the
binding site of high a⁄nity for drugs. Phe, a bulky aromatic
residue, at position 647 might cause shift of the S6 to change
the shape of the drug binding site, which results in the reduced
e¡ects of various drugs.
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